根据协议条款，复宏汉霖将从买卖中获得5.41亿美元的潜在支出，其中7300万美元为买卖首付款。Organon还可以选择就复宏汉霖自主开发的伊匹木单抗生物类似药HLX13的全球商业化独家权益进行会谈。Organon为一家跨国药企，专注于女性全生命周期的健康，在女性健康、生物类似药和成熟品牌领域拥有超过60款上市产品，业务覆盖逾140个国家。此次复宏汉霖携手Organon，将进一步提升公司产品在全球市场的可及性和影响力，为更多患者带来希望。

复宏汉霖董事长、执行董事兼首席执行官张文杰先生表示：“我们很高兴与Organon达成此项合作。Organon的研发理念是围绕病患需求来建立业务，并着力在女性健康领域为患者提供更多治疗方案，这与我们不断以来坚守的‘为全球病患提供高质量的创重生物药’的理念高度契合。将来，我们也将持续开发更多基于临床和市场需求的创新产品，以造福更多全球病患。”

以临床需求为导向，复宏汉霖积极推进国际化规划，加快国际运营战略步伐，已建成一体化生物制药平台，创新才能贯穿研发、消费及商业运营全产业链。公司协同中美两地创新中心及全球产品开发团队，持续加码创新，夯实丰富的多元化产品管线，已累计在全球范围内获得超过70项临床实验同意，并同步在中国、欧盟、美国和澳大利亚等国家和地区开展20多项临床实验。消费方面，公司严厉遵照按照国际药品消费质量管理规范（GMP）标准进行消费和质量管控，现有商业化产能共计48000L，管线内产品均由公司自主消费，积累了从临床到商业化各阶段产品的丰富消费经验。此外，公司搭建了超过800人的自主商业化团队担任核心肿瘤产品的商业化推行，同时与全球知名制药企业合作，产品授权覆盖欧美主流生物药市场和新兴市场。

复宏汉霖自主研制的帕妥珠单抗生物类似药（重组抗HER2结构域II人源化单克隆抗体注射液），有望与曲妥珠单抗和化疗联合用于HER2阳性早期乳腺癌的辅助治疗、新辅助治疗以及与曲妥珠单抗和多西他赛联合用于HER2阳性转移性或不可切除的局部复发性乳腺癌的治疗。目前，其I期临床研讨已达到次要研讨终点，研讨结果证明HLX11与美国、欧盟和中国市售的原研帕妥珠单抗的药物代谢动力学特征及安全性类似。

复宏汉霖自主研制的地舒单抗生物类似药（重组抗RANKL全人单克隆抗体注射液）。目前地舒单抗在全球范围内已获批用于一系列顺应症，如高危骨折风险的女性绝经后骨质疏松症、实体瘤骨转移和多发性骨髓瘤患者的骨相关事情预防，以及骨巨细胞瘤等。

复宏汉霖自主研制的伊匹木单抗生物类似药（重组抗CTLA-4全人单克隆抗体注射液）。伊匹木单抗可用于不可切除或转移性黑色素瘤的治疗和黑色素瘤的辅助治疗，以及肾细胞癌、结直肠癌、肝细胞癌、非小细胞肺癌、恶性胸膜间皮瘤和食管癌的治疗。

复宏汉霖（2696.HK）是一家国际化的创重生物制药公司，努力于为全球患者提供可负担的高质量生物药，产品覆盖肿瘤、本身免疫疾病、眼科疾病等领域，已在中国上市5款产品，在欧洲上市1款产品，13项顺应症获批，2个上市注册恳求获得中国药监局受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心才能贯穿研发、消费及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品消费质量管理规范（GMP）标准进行消费和质量管控，不断夯实一体化综合消费平台，其中，上海徐汇基地已获得中国和欧盟药品GMP认证，松江基地（一）也已获得中国GMP认证。

复宏汉霖前瞻性规划了一个多元化、高质量的产品管线，涵盖20多种创新单克隆抗体，并片面推进基于自有抗PD-1单抗H药汉斯状^®的肿瘤免疫联合疗法。继国内首个生物类似药汉利康^®（利妥昔单抗）、中国首个自主研发的中欧双批单抗药物汉曲优^®（曲妥珠单抗，欧洲商品名：Zercepac^®）、汉达远^®（阿达木单抗）和汉贝泰^®（贝伐珠单抗）相继获批上市，创新产品汉斯状^®（斯鲁利单抗）已获批用于治疗微卫星高度不波动（MSI-H）实体瘤，其鳞状非小细胞肺癌和广泛期小细胞肺癌两项顺应症的上市注册恳求也正在审评中。公司亦同步就12个产品、10个免疫联合治疗方案在全球范围内开展20多项临床实验，对外授权片面覆盖欧美主流生物药市场和众多新兴市场。

HLX11 (anti-HER2 domain II humanised monoclonal antibody injection), a biosimilar candidate of pertuzumab, is independently developed by Henlius, which can be potentially used in combination with trastuzumab and chemotherapy as neoadjuvant or adjuvant treatment for HER2 positive early breast cancer and in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic or unresectable locally recurrent breast cancer patients. To date, HLX11 has met primary endpoint in a Phase 1 clinical trial, showing similar pharmacokinetic and safety profiles to the reference drugs from different sources.

HLX14 (recombinant anti-RANKL human monoclonal antibody injection), a biosimilar candidate of denosumab, is independently developed by Henlius. Denosumab has been approved worldwide for a range of indications such as for the treatment of postmenopausal women with osteoporosis at high risk for fracture, giant cell tumor of bone, skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, etc.

HLX13 (recombinant anti-CTLA-4 fully human monoclonal antibody injection), a biosimilar candidate of ipilimumab, is independently developed by Henlius. Ipilimumab is used for the treatment of certain patients with unresectable or metastatic melanoma, as adjuvant treatment of certain patients with cutaneous melanoma, certain patients with Renal Cell Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma and Esophageal Cancer.

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 5 products have been launched in China, 1 in Europe, 13 indications approved worldwide, and 2 New Drug Applications (NDAs) accepted for review in China. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Plant certificated by China and the EU GMP and Songjiang First Plant certificated by China GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name in Europe: Zercepac^®), the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumors and its NDA for the treatment of squamous non-small cell lung cancer and extensive small-cell lung cancer (ES-SCLC) are under review. What's more, Henlius has conducted over 20 clinical studies for 12 products and 10 combination therapies.